Skip to main content
. Author manuscript; available in PMC: 2018 Sep 1.
Published in final edited form as: Mol Cancer Ther. 2017 Jun 15;16(9):1779–1790. doi: 10.1158/1535-7163.MCT-16-0848

Figure 6. Hsp90 inhibition is synergistic with PI3K/mTOR inhibition in BL.

Figure 6

(A) Namalwa, Daudi, DG-75, and Ramos cells were treated with increasing doses of PU-H71 alone, a PI3K inhibitor as indicated alone, or the combination. Cell viability was measured using CellTiter-Glo. Synergy was calculated using Compusyn. CI values <0.9 are synergistic. Results represent the mean of the experiment performed in triplicate +/− SEM. (B) NOD-SCID mice were injected with 1 × 107 Namalwa cells. When tumors reached 150–200mm3 mice were treated with PU-H71, BEZ235, the combination, or vehicle control. Tumor growth plot of mice treated with PU-H71, BEZ235, the combination, or vehicle control. Error bars represent SEM. (C) Growth of tumor as measured by area under the curve. Average tumor growth is represented on the y axis which represents tumor volume (mm3)/time (days). Error bars represent SEM.

HHS Vulnerability Disclosure